Nevertheless, the development of HERV-K (HML-2)-specific CAR-T-cell therapy represents an exciting avenue for the advancement of cancer immunotherapy and offers hope for improved treatment outcomes for patients with breast cancer, melanoma, and other solid tumors expressing HERV-K (HML-2) [155]. The gene discussed is CLEC10A; the disease is cancer.